Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 18/20 | 0.81 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.81 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.71 |
| ▸ | HRH1 | P35367 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Maleic Acid SCHEMBL602941 | 0.93 | ALOX15 (0.84) | HRH4HRH3ALOX15HRH1 | |
| Fumaric Acid SCHEMBL602943 | 0.93 | ALOX15 (0.84) | HRH4HRH3ALOX15HRH1 | |
| Maleic Acid SCHEMBL29404707 | 0.93 | ALOX15 (0.84) | HRH4HRH3ALOX15HRH1 | |
| Maleic Acid SCHEMBL20162482 | 0.93 | ALOX15 (0.84) | HRH4HRH3ALOX15HRH1 | |
| Jnj-7777120 SCHEMBL18486196 | 0.92 | HRH4 (0.80) | HRH4HRH3ALOX15HRH1 | |
| SCHEMBL16939347 | 0.90 | HRH4 (1.00) | HRH4HRH3ALOX15HRH1 | |
| SCHEMBL29385016 | 0.90 | HRH4 (1.00) | HRH4HRH3ALOX15HRH1 | |
| SCHEMBL604697 | 0.86 | HRH4 (0.64) | HRH4HRH3ALOX15HRH1 | |
| SCHEMBL606417 | 0.86 | HRH4 (0.81) | HRH4HRH3ALOX15 | |
| SCHEMBL602130 | 0.85 | HRH4 (0.81) | HRH4HRH3ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2890373-B1 | HISTAMINE 4 RECEPTOR PARTIAL AGONISTS, INVERSE AGONISTS OR ANTAGONISTS FOR USE IN TREATING CHRONIC UVEITIS | UCL BUSINESS PLC (GB) | 2017-11-08 | — | — | EP | claimed |
| US-20170056397-A1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2017-03-02 | — | — | US | claimed |
| US-9579318-B2 | Histamine 4 receptor partial agonists, inverse agonists or antagonists for use in treating non-autoimmune uveitis | UCL BUSINESS PLC (GB) | 2017-02-28 | — | — | US | claimed |
| US-9526725-B2 | Selective histamine H4 receptor antagonists for the treatment of vestibular disorders | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2016-12-27 | — | — | US | claimed |
| EP-2382013-B1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS. | INSERM INST NAT DE LA SANTÉ ET DE LA RECH MÉDICALE (FR) | 2016-07-13 | — | — | EP | claimed |
| US-20150209348-A1 | HISTAMINE 4 RECEPTOR PARTIAL AGONISTS, INVERSE AGONISTS OR ANTAGONISTS FOR USE IN TREATING NON-AUTOIMMUNE UVEITIS | UCL BUSINESS PLC (GB) | 2015-07-30 | — | — | US | claimed |
| EP-2890373-A1 | HISTAMINE 4 RECEPTOR PARTIAL AGONISTS, INVERSE AGONISTS OR ANTAGONISTS FOR USE IN TREATING NON-AUTOIMMUNE UVEITIS | UCL Business Plc. (GB) | 2015-07-08 | — | — | EP | claimed |
| WO-2014130759-A1 | METHODS OF USING HISTAMINE RECEPTOR AGONISTS AND ANTAGONISTS | UNIVERSITY OF ROCHESTER (US) | 2014-08-28 | — | — | WO | claimed |
| WO-2014033480-A1 | HISTAMINE 4 RECEPTOR PARTIAL AGONISTS, INVERSE AGONISTS OR ANTAGONISTS FOR USE|IN TREATING NON-AUTOIMMUNE UVEITIS | UCL BUSINESS PLC (GB) | 2014-03-06 | — | — | WO | claimed |
| US-20130296327-A1 | SUBSTITUTED HETEROCYLIC COMPOUNDS | INCYTE CORPORATION | 2013-11-07 | — | — | US | claimed |
| US-20120039913-A1 | Selective Histamine H4 Receptor Antagonists for the Treatment of Vestibular Disorders | INSERM (institut National de la Sante de la Recher Medicale) (FR) | 2012-02-16 | — | — | US | claimed |
| EP-2382013-A1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS. | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2011-11-02 | — | — | EP | claimed |
| US-20100240671-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | INCYTE CORPORATION (US) | 2010-09-23 | — | — | US | claimed |
| WO-2010108059-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES AS ANTAGONISTS OF THE HISTAMINE H4 RECEPTOR | INCYTE CORPORATION (US) | 2010-09-23 | — | — | WO | claimed |
| US-20100173901-A1 | Substituted Heterocyclic Compounds | INCYTE CORPORATION (US) | 2010-07-08 | — | — | US | claimed |
| WO-2010072829-A1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS. | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2010-07-01 | — | — | WO | claimed |
| EP-2201982-A1 | Histamine H4 receptor antagonists for the treatment of vestibular disorders | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2010-06-30 | — | — | EP | claimed |
| EP-1545532-A2 | HETEROCYCLIC COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-06-29 | — | — | EP | claimed |
| US-20040058934-A1 | Heterocyclic compounds | JANSSEN PHARMACEUTIC, N.V. (BE) | 2004-03-25 | — | — | US | claimed |
| WO-2004022060-A2 | (1H-BENZOIMIDAZOL-2-YL)-(PIPERAZINYL)-METHANONE DERIVATIVES AND RELATED COMPOUNDS AS HISTAMINE H4-RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-03-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173901-A1 | Substituted Heterocyclic Compounds | HRH4, HRH2, HRH1 | HRH4 1/4885HRH3 4/4885ALOX15 426/4885 |
| US-20130296327-A1 | SUBSTITUTED HETEROCYLIC COMPOUNDS | HRH4, HRH2, HRH1 | HRH4 1/4885HRH3 4/4885ALOX15 319/4885 |
| US-20150209348-A1 | HISTAMINE 4 RECEPTOR PARTIAL AGONISTS, INVERSE AGONISTS OR ANTAGONISTS FOR USE IN TREATING NON-AUTOIMMUNE UVEITIS | HRH4, HRH3, HRH2 | HRH4 1/4885HRH3 2/4885ALOX15 2525/4885 |
| US-20100240671-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | HRH4, HRH2, HRH1 | HRH4 1/4885HRH3 4/4885ALOX15 421/4885 |
| US-20040058934-A1 | Heterocyclic compounds | HRH4, HRH2, HRH1 | HRH4 1/4885HRH3 4/4885ALOX15 636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.